Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708329 | 0.80 | TSHR (0.59) | HTTMAOAMAOBIDO1TDO2 | |
| SCHEMBL29573338 | 0.80 | TSHR (0.59) | HTTMAOAMAOBIDO1TDO2 | |
| SCHEMBL10456467 | 0.80 | HTT (0.43) | TAAR1HTTMAOAMAOBIDO1 | |
| SCHEMBL10738640 | 0.79 | TAAR1 (0.53) | TAAR1HTR2AHTR2CHTR2BHTT | |
| SCHEMBL6680371 | 0.78 | HTT (0.50) | TAAR1HTTMAOAMAOBIDO1 | |
| SCHEMBL2401582 | 0.78 | HTT (0.46) | HTR2CHTR2BHTTMAOAMAOB | |
| SCHEMBL708904 | 0.78 | HTT (0.42) | HTTMAOAMAOBIDO1TDO2 | |
| SCHEMBL31627096 | 0.77 | SLC7A5 (0.38) | TAAR1HTR2AHTTMAOAMAOB | |
| SCHEMBL11111739 | 0.77 | IDO1 (0.42) | TAAR1HTR2AHTR2CHTR2BHTT | |
| SCHEMBL1471049 | 0.77 | IDO1 (0.42) | TAAR1HTR2AHTR2CHTR2BHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107690281-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2018-02-13 | — | — | CN | disclosed |
| US-7078567-B2 | Amination process | JOHNSTON JEFFREY N | 2006-07-18 | — | — | US | disclosed |
| US-20040082778-A1 | Amination process | JOHNSTON JEFFREY N (US) | 2004-04-29 | — | — | US | disclosed |
| US-6670479-B2 | An sp2 hybridized radical is reacted with an azomethine group to form pyrrolidine and indole compounds | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2003-12-30 | — | — | US | disclosed |
| WO-2002072547-A1 | AMINATION PROCESS | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002070439-A2 | AMINATION PROCESS | JOHNSTON, JEFFREY, N. | 2002-09-12 | — | — | WO | disclosed |
| US-20020128490-A1 | Amination process | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-09-12 | — | — | US | disclosed |
| EP-0163948-B1 | PROCESS FOR PRODUCING AN INDOLINE | IHARA CHEMICAL IND CO | 1989-08-16 | — | — | EP | disclosed |
| US-4673749-A | CYCLIZATION OF 2-HOLOGENO PHENETHYLAMINES WITH COPPER CATALYS T AND ALKALI DEHYROHALOGENATING AGENT | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1987-06-16 | — | — | US | disclosed |
| EP-0163948-A1 | Process for producing an indoline | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
| US-4280958-A | COPPER-TYPE CATALYST USED IN CYCLIZATION OF A HALOGENOPHENETHYLAMINE IN THE PRESENCE OF AN AMINE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1981-07-28 | — | — | US | disclosed |
| US-4159271-A | CYCLIZATION OF A 2-HALOGENOPHENETHYLAMINE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082778-A1 | Amination process | IDO2, INMT, IDO1 | TAAR1 984/4885HTR2A 158/4885HTR2C 186/4885 |
| US-20020128490-A1 | Amination process | IDO2, INMT, IDO1 | TAAR1 760/4885HTR2A 173/4885HTR2C 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.